LONDON--(BUSINESS WIRE)--Aug 29, 2018--According to the latest market research report released by Technavio, the global human microbiome therapeutics market is expected to accelerate at a CAGR of almost 14% during the forecast period. The growing prevalence of chronic diseases is one of the key factors triggering the growth of the market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180829005495/en/

Technavio has published a new market research report on the global human microbiome therapeutics market from 2018-2022. (Graphic: Business Wire)

This research report titled ‘ ’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. It also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.

This report is available at a USD 1,000 discount for a limited time only:

The market research analysis categorizes the global human microbiome therapeutics market into the following regions:

APAC EMEA Americas

In 2017, the Americas accounted for 45% of the global market due to a substantial investment in the healthcare sector by economic giants such as the US.

Global human microbiome therapeutics market: Top emerging trend

The increase in industry-academia collaboration is an emerging trend in the human microbiome therapeutics space. The key players in the global pharmaceutical drugs market are increasingly extending their support to academic institutions to support R&D of innovative products for diabetes care. Collaborations between companies and academic institutions enable the amalgamation of research expertise of academic institutions with marketing intelligence of pharmaceutical companies. Such collaborations also generate funds to conduct trial studies. The increase in public-private partnerships, especially in the developing countries fuel the development of novel therapeutics such as human microbiome therapeutics.

Looking for more information on this market?

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Technavio’s report provides expert market research on the following topics:

Executive Report

Market Outline Global Human Microbiome Therapeutics Market Overview

Market Insights

Market Sizing and Forecasts Market Growth Market Drivers and Challenges Key Emerging Trends

Market Segmentation Analysis

Regional comparison (APAC, Americas, and EMEA) Key leading countries Market segmentation by therapeutic application (gastrointestinal disorders and immunological conditions)

Vendor Landscape

Vendor classification Market positioning of vendors Competitive scenario Analysis of top vendors (ENTEROME Bioscience, Rebiotix, Seres Therapeutics, and Vedanta Biosciences)

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20180829005495/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: HEALTH OTHER HEALTH RESEARCH OTHER SCIENCE SCIENCE

SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 08/29/2018 10:48 AM/DISC: 08/29/2018 10:48 AM

http://www.businesswire.com/news/home/20180829005495/en